U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C12H13ClN4
Molecular Weight 248.711
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PYRIMETHAMINE

SMILES

CCC1=NC(N)=NC(N)=C1C2=CC=C(Cl)C=C2

InChI

InChIKey=WKSAUQYGYAYLPV-UHFFFAOYSA-N
InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)

HIDE SMILES / InChI

Molecular Formula C12H13ClN4
Molecular Weight 248.711
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9554869

Pyrimethamine, sold under the trade name Daraprim, is one of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. In addition it was approved in Chemoprophylaxis of Malaria. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas. Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins. Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase-thymidylate synthase and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and Toxoplasma gondii. Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans. The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
DARAPRIM

Approved Use

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia. Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

Launch Date

1953
Curative
DARAPRIM

Approved Use

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia. Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

Launch Date

1953
Preventing
DARAPRIM

Approved Use

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia. Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

Launch Date

1953
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.059 μg/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Zidovudine
PYRIMETHAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
502.9 μg × h/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Zidovudine
PYRIMETHAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
96 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRIMETHAMINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
190.56 h
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Zidovudine
PYRIMETHAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRIMETHAMINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources:
healthy, 1
Disc. AE: Vomiting, Convulsions...
AEs leading to
discontinuation/dose reduction:
Vomiting
Convulsions (severe)
Cyanosis
Sources:
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources:
healthy, 1
Disc. AE: Convulsions, Respiratory failure...
AEs leading to
discontinuation/dose reduction:
Convulsions
Respiratory failure (grade 5)
Sources:
1.2 g single, oral
Overdose
healthy, 2
Disc. AE: Cyanosis, Vomiting...
AEs leading to
discontinuation/dose reduction:
Cyanosis
Vomiting (severe)
Convulsions
Apnoea
Haematemesis
Cardiac failure (grade 5)
Sources:
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 2
Disc. AE: Convulsions, Vomiting...
AEs leading to
discontinuation/dose reduction:
Convulsions (severe)
Vomiting
Cyanosis
Collapse
Sources:
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources:
healthy, 3
Disc. AE: Convulsions, Unconsciousness...
AEs leading to
discontinuation/dose reduction:
Convulsions (grade 5)
Unconsciousness (grade 5)
Sources:
300 mg single, oral
Overdose
unhealthy
Disc. AE: Convulsions, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Convulsions
Abdominal pain
Nausea
Vomiting (severe)
Excitability
Respiratory depression (grade 5)
Circulatory collapse (grade 5)
Sources:
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Folate deficiency...
AEs leading to
discontinuation/dose reduction:
Folate deficiency
Sources:
AEs

AEs

AESignificanceDosePopulation
Cyanosis Disc. AE
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources:
healthy, 1
Vomiting Disc. AE
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources:
healthy, 1
Convulsions severe
Disc. AE
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources:
healthy, 1
Convulsions Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources:
healthy, 1
Respiratory failure grade 5
Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources:
healthy, 1
Apnoea Disc. AE
1.2 g single, oral
Overdose
healthy, 2
Convulsions Disc. AE
1.2 g single, oral
Overdose
healthy, 2
Cyanosis Disc. AE
1.2 g single, oral
Overdose
healthy, 2
Haematemesis Disc. AE
1.2 g single, oral
Overdose
healthy, 2
Cardiac failure grade 5
Disc. AE
1.2 g single, oral
Overdose
healthy, 2
Vomiting severe
Disc. AE
1.2 g single, oral
Overdose
healthy, 2
Collapse Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 2
Cyanosis Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 2
Vomiting Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 2
Convulsions severe
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, 2
Convulsions grade 5
Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources:
healthy, 3
Unconsciousness grade 5
Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources:
healthy, 3
Abdominal pain Disc. AE
300 mg single, oral
Overdose
unhealthy
Convulsions Disc. AE
300 mg single, oral
Overdose
unhealthy
Excitability Disc. AE
300 mg single, oral
Overdose
unhealthy
Nausea Disc. AE
300 mg single, oral
Overdose
unhealthy
Circulatory collapse grade 5
Disc. AE
300 mg single, oral
Overdose
unhealthy
Respiratory depression grade 5
Disc. AE
300 mg single, oral
Overdose
unhealthy
Vomiting severe
Disc. AE
300 mg single, oral
Overdose
unhealthy
Folate deficiency Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [Activation 10 uM]
inconclusive [Activation 39.8107 uM]
inconclusive [Activation 5.0119 uM]
inconclusive [Activation 7.9433 uM]
inconclusive [Activation >10 uM]
no [Activation >10 uM]
no
no
weak [IC50 200.1 uM]
yes [IC50 0.131 uM]
yes [IC50 1.8 uM]
yes [IC50 4.55 uM]
yes [IC50 45.1 uM]
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.
1990 Aug
In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.
1990 Aug
Resolution of acute renal failure in toxoplasmic encephalitis despite continuance of sulfadiazine.
1990 Jul-Aug
In vitro and in vivo effects of doxycycline on Toxoplasma gondii.
1990 May
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.
1991 Jul
Activity of minocycline against Toxoplasma gondii infection in mice.
1991 May
Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis.
1991 May
Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.
1992 May
Antituberculosis activity of certain antifungal and antihelmintic drugs.
1999
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.
2000 Nov
Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline.
2000 Oct
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.
2000 Sep
Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii.
2001 Jan
[Malaria vector control in Cameroon: past, present, future. Reflections].
2001 Jul
Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
2001 Nov
Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro.
2003 Aug
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
2004 Jan 15
Pyrimethamine (2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine) induces apoptosis of freshly isolated human T lymphocytes, bypassing CD95/Fas molecule but involving its intrinsic pathway.
2005 Dec
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Hydrogen-bonding patterns in pyrimethaminium dinitrate.
2005 Oct
Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug.
2005 Oct 20
Sulfonamide crystals and acute renal failure.
2006 Jun
Presumed dapsone-induced drug hypersensitivity syndrome causing reversible hypersensitivity myocarditis and thyrotoxicosis.
2006 Nov
[Acute renal failure due to sulfadiazine crystalluria].
2007 May
Suppression of telomerase activity by pyrimethamine: implication to cancer.
2007 Oct
A comparison of vitamin A and leucovorin for the prevention of methotrexate-induced micronuclei production in rat bone marrow.
2008 Dec
Anti-toxoplasmosis effects of oleuropein isolated from Fraxinus rhychophylla.
2008 Dec
ECVAM retrospective validation of in vitro micronucleus test (MNT).
2008 Jul
Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism.
2008 Jul 1
Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: part III: placental malaria, maternal health, and public health.
2008 Mar
Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis.
2008 Nov 1
HIV, TB, Malaria, Filaria and Kala azar.
2008 Oct
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children.
2010 Aug 17
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
2010 May 15
Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.
2010 Nov
Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: a novel immunomodulatory mechanism of action for an old antimalarial drug?
2010 Nov
Toxoplasma gondii: inhibitory activity and encystation effect of securinine and pyrrolidine derivatives on Toxoplasma growth.
2011 Feb
Use of the NP-40 detergent-mediated assay in discovery of inhibitors of beta-hematin crystallization.
2011 Jul
Crystal structure of β-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone.
2011 Mar 10
Antiplasmodial and analgesic activities of Clausena anisata.
2012 Mar
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.
2012 Oct
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.
2012 Oct 16
Identification of a new chemical class of antimalarials.
2012 Sep 1
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models.
2013
A new protoberberine alkaloid from Meconopsis simplicifolia (D. Don) Walpers with potent antimalarial activity against a multidrug resistant Plasmodium falciparum strain.
2013 Dec 12
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
2013 Jan 1
Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs.
2013 Jul
Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
2013 Mar
A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
2013 Mar 1
Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
2014 Mar 3
Patents

Sample Use Guides

Toxoplasmosis: The adult starting dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g., sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy. The dosage may then be reduced to about one half that previously given for each drug and continued for an additional 4 to 5 weeks. The pediatric dosage of DARAPRIM (PYRIMETHAMINE) is 1 mg/kg/day divided into 2 equal daily doses; after 2 to 4 days this dose may be reduced to one half and continued for approximately 1 month. The usual pediatric sulfonamide dosage is used in conjunction with DARAPRIM. Treatment of Acute Malaria: at a dosage of 25 mg daily for 2 days with a sulfonamide will initiate transmission control and suppression of non-falciparum malaria. The adult dosage for acute malaria is 50 mg for 2 days; children 4 through 10 years old may be given 25 mg daily for 2 days. In any event, clinical cure should be followed by the once-weekly regimen described below for chemoprophylaxis. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse, i.e., for at least 10 weeks in each case. For Chemoprophylaxis of Malaria: Adults and pediatric patients over 10 years — 25 mg (1 tablet) once weekly. Children 4 through 10 years — 12.5 mg (1/2 tablet) once weekly. Infants and children under 4 years — 6.25 mg (1/4 tablet) once weekly.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The cytotoxic influence of Pyrimethamine on prostate cell line was investigated using an in vitro colometric assay. Cytotoxicity analysis of pyrimethamine revealed a dose-dependent fashion. An apoptotic influence of pyrimethamine was also confirmed by data obtained from TUNEL assay. Dose-dependent inhibitory effect on matrix metalloproteinases (MMP) was seen in pyrimethamine. A potent inhibitory effect of pyrimethamine was also established by data achieved from TRAPeze telomerase detection kit.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:55:01 GMT 2025
Edited
by admin
on Mon Mar 31 17:55:01 GMT 2025
Record UNII
Z3614QOX8W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DARAPRIM
Preferred Name English
PYRIMETHAMINE
EP   GREEN BOOK   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
PYRIMETHAMINE [MART.]
Common Name English
PYRIMETHAMINE [WHO-IP]
Common Name English
FANSIDAR COMPONENT PYRIMETHAMINE
Common Name English
RP-4753
Code English
2,4-DIAMINO-5-(P-CHLOROPHENYL)-6-ETHYLPYRIMIDINE
Common Name English
PYRIMETHAMINE [VANDF]
Common Name English
CHLORIDINE
Common Name English
Pyrimethamine [WHO-DD]
Common Name English
WR-2978
Code English
PYRIMETHAMINE [JAN]
Common Name English
PYRIMETHAMINE [USP MONOGRAPH]
Common Name English
PYRIMETHAMINE [IARC]
Common Name English
pyrimethamine [INN]
Common Name English
PYRIMETHAMINE [MI]
Common Name English
PYRIMETHAMINE [GREEN BOOK]
Common Name English
GNF-PF-5586
Code English
TCMDC-125860
Code English
PYRIMETHAMINE [EP MONOGRAPH]
Common Name English
PYRIMETHAMINE [USP-RS]
Common Name English
PYRIMETHAMINUM [WHO-IP LATIN]
Common Name English
2,4-PYRIMIDINEDIAMINE, 5-(4-CHLOROPHENYL)-6-ETHYL-
Systematic Name English
NSC-3061
Code English
PYRIMETHAMINE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548044
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
NDF-RT N0000000191
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
NDF-RT N0000000191
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
WHO-ATC P01BD51
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
NDF-RT N0000175934
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1 (SUL/PYR)
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
FDA ORPHAN DRUG 232206
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
EPA PESTICIDE CODE 600071
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.5.4
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
IARC Pyrimethamine
NCI_THESAURUS C271
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
NCI_THESAURUS C2153
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
WHO-ATC P01BF04
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
CFR 21 CFR 520.2215
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
WHO-VATC QP51AX51
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
WHO-ATC P01BD01
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
Code System Code Type Description
MERCK INDEX
m9368
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY Merck Index
MESH
D011739
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
DAILYMED
Z3614QOX8W
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
RS_ITEM_NUM
1589007
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
PUBCHEM
4993
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
ChEMBL
CHEMBL36
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PYRIMETHAMINE
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS and acetone R. Category: Antimalarial. Storage: Pyrimethamine should be kept in a well-closed container, protected from light. Definition: Pyrimethamine contains not less than 99.0% and not more than 101.0% of C12H13ClN4, calculated with reference to the dried substance.
WIKIPEDIA
PYRIMETHAMINE
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
INN
2215
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
RXCUI
9010
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY RxNorm
CAS
58-14-0
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
CHEBI
8673
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
IUPHAR
4800
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
DRUG BANK
DB00205
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
FDA UNII
Z3614QOX8W
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
EVMPD
SUB10169MIG
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
NCI_THESAURUS
C788
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
NSC
3061
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
EPA CompTox
DTXSID9021217
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
SMS_ID
100000080868
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-364-2
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
LACTMED
Pyrimethamine
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
LACTMED
Sulfadoxine and Pyrimethamine
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
DRUG CENTRAL
2332
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
HSDB
8042
Created by admin on Mon Mar 31 17:55:01 GMT 2025 , Edited by admin on Mon Mar 31 17:55:01 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC